Predicting drug responsiveness in human cancers using genetically engineered mice.

ABSTRACT:

Purpose

To use genetically engineered mouse models (GEMM) and orthotopic syngeneic murine transplants (OST) to develop gene expression-based predictors of response to anticancer drugs in human tumors. These mouse models offer advantages including precise genetics and an intact microenvironment/immune system.

Experimental design

We examined the efficacy of 4 chemotherapeutic or targeted anticancer drugs, alone and in combination, using mouse models representing 3 distinct breast cancer subtypes: Basal-like (C3(1)-T-antigen GEMM), Luminal B (MMTV-Neu GEMM), and Claudin-low (T11/TP53-/- OST). We expression-profiled tumors to develop signatures that corresponded to treatment and response, and then tested their predictive potential using human patient data.

Results

Althoug

SUBMITTER: Usary J 

PROVIDER: S-EPMC3778918 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature